

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6689628

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XIAOFENG XIONG	06/12/2018
DEBRA ODINK	06/12/2018
CHRISTINE M.N. SMITH	06/12/2018
COLLEEN M. CRAIG	06/18/2018
RECEIVING PARTY DATA	
Name:	EIGER BIOPHARMACEUTICALS, INC.
Street Address:	2155 PARK BOULEVARD
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94306
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16461329
Application Number:	17306782
CORRESPONDENCE DATA	
Fax Number:	(404)541-3178
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	4048153500
Email:	wmartin-gayle@kilpatricktownsend.com
Correspondent Name:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1:	1100 PEACHTREE STREET, N.E.
Address Line 2:	SUITE 2800
Address Line 4:	ATLANTA, GEORGIA 30309
ATTORNEY DOCKET NUMBER:	097854-1246028 (001620US)
NAME OF SUBMITTER:	WILSA MARTIN-GAYLE
SIGNATURE:	/Wilsa Martin-Gayle/
DATE SIGNED:	05/03/2021
Total Attachments: 5	

source=Assignment from 001610PC#page1.tif
source=Assignment from 001610PC#page2.tif
source=Assignment from 001610PC#page3.tif
source=Assignment from 001610PC#page4.tif
source=Assignment from 001610PC#page5.tif

ASSIGNMENT
(Patent Application)

I, the undersigned, have invented certain inventions and improvements disclosed in a PCT patent application entitled

“BUFFERED FORMULATIONS OF EXENDIN (9-39)”

which was filed with the U.S. Receiving Office on November 21, 2017 and assigned International Application No. PCT/US2017/062838.

For good and valuable consideration, the receipt and sufficiency of which I acknowledge, I:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Eiger BioPharmaceuticals, Inc.**, a corporation of the State of Delaware having a principal place of business at 2155 Park Boulevard, Palo Alto, CA 94306; and **The Board of Trustees of the Leland Stanford Junior University**, a non-profit organization duly organized under and pursuant to the laws of California, and having its principal place of business at the Office of the General Counsel, Building 170, 3rd Floor, Main Quad P.O. Box 20386 Stanford, CA 94305 (“Assignees”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this

ASSIGNMENT

BUFFERED FORMULATIONS OF EXENDIN (9-39)

International Application No. PCT/US2017/062838

Attorney Docket No. 097854-001610PC-1065856

Page 2 of 2

paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

(d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon me, as well as my heirs, legal representatives, and assigns.
5. Promise and affirm that I have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside my signature.

Signature: _____


Colleen M. Craig

Date: 06/18/18

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a PCT patent application entitled

“BUFFERED FORMULATIONS OF EXENDIN (9-39)”

which was filed with the U.S. Receiving Office on November 21, 2017 and assigned International Application No. PCT/US2017/062838.

For good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:

1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Eiger BioPharmaceuticals, Inc.**, a corporation of the State of Delaware having a principal place of business at 2155 Park Boulevard, Palo Alto, CA 94306 (“Assignee”), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.


Signed on the date indicated beside my signature.

Signature: _____
Xiaofeng Xiong

Date: _____

Signature: _____
Debra Odink


Date: _____

Signature:  _____
Christine M.N. Smith


Date: 6/12/2018

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Signed on the date indicated beside my signature.

Signature: 
Xiaofeng Xiong

Date: 6/12/2018

Signature: 
Debra Odink

Date: 12 June 2018

Signature: _____
Christine M.N. Smith

Date: _____